| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.8 |
| mRNA | nakiterpiosin | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.8 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |